Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer - Wikidata - wikimedia - TriplyDB

Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer

Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer

http://www.wikidata.org/entity/Q33862861

about

Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy Immunotherapy for stage I-III non-small cell lung cancer treated with surgery or radiotherapy with curative intent Immunobiology and immunotherapy in genitourinary malignancies Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis Engineering opportunities in cancer immunotherapy Whole Tumor Antigen Vaccines: Where Are We?Biomarkers for glioma immunotherapy: the next generation Alternative Treatments For Melanoma: Targeting BCL-2 Family Members to De-Bulk and Kill Cancer Stem Cells Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise Pentoxifylline Inhibits WNT Signalling in β-Cateninhigh Patient-Derived Melanoma Cell Populations Novel delivery approaches for cancer therapeutics.Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics.Identification of CD112R as a novel checkpoint for human T cells.Arsenic trioxide inhibits tumor-induced myeloid-derived suppressor cells and enhances T-cell activity.HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?Melanoma of non-sun exposed skin in a man with previous prostate cancer: recognition of a recently confirmed association.Cancer vaccines: Trafficking of tumor-specific T cells to tumor after therapeutic vaccination.Current status of cancer immunotherapy Cross-sectional and longitudinal analysis of cancer vaccination trials registered on the US Clinical Trials Database demonstrates paucity of immunological trial endpoints and decline in registration since 2008 Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers.In Vitro Administration of Gold Nanoparticles Functionalized with MUC-1 Protein Fragment Generates Anticancer Vaccine Response via Macrophage Activation and Polarization Mechanism.Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.New Immunotherapy Strategies in Breast Cancer.Initial viral load determines the magnitude of the human CD8 T cell response to yellow fever vaccination.Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen TLR5 Ligand-Secreting T Cells Reshape the Tumor Microenvironment and Enhance Antitumor Activity.Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review.Combining TGF-β1 knockdown and miR200c administration to optimize antitumor efficacy of B16F10/GPI-IL-21 vaccine.Molecular profiling of CD8 T cells in autochthonous melanoma identifies Maf as driver of exhaustion.Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set.Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance.The Impact of Tonsillectomy upon the Risk of Oropharyngeal Carcinoma Diagnosis and Prognosis in the Danish Cancer Registry IL-27 induces the expression of IDO and PD-L1 in human cancer cells.Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview Diversity and divergence of the glioma-infiltrating T-cell receptor repertoire.Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy.Comprehensive analyses of tumor immunity: implications for cancer immunotherapy.

P2860

Q24187274-17E3A946-8892-4127-ACEE-C8A41411CA8A Q24194081-CD24EA7A-BE5B-4851-9EED-F3EB2675DE17 Q26738668-B3493DD6-B1E1-4258-8495-A27D574EDD90 Q26747792-770D35E4-7BD8-422C-9D8C-DC8FBEA8D631 Q26769728-881BF419-94C0-44E0-A82E-EF5FBF635694 Q26776373-E707BE10-17E9-4090-9799-81775B412469 Q26783866-8893D7D3-7251-44E8-9B34-71AF246E7EAA Q26825496-932D0395-A49E-406A-AA38-2433CE61E5AD Q28084243-3ECA33C6-F3AE-4A57-8A79-B97C7C20B3B7 Q28088334-AA2FC88A-E5D2-4FBB-8712-5B3554451385 Q28552213-473F0AA1-0EAF-44B2-AD90-41A0B3B552E4 Q30368171-1B1B7015-2E99-4686-AF2D-83A38E2B7814 Q30381467-4F5A8DED-6DEA-4808-B38D-53EE2C64A051 Q33289401-1E9E2B72-4DB5-4FF8-838C-A261F838DFCB Q33598739-2F0B509C-4F6C-4390-BA6E-97E061A0BF7C Q33632104-D6DD4B59-1778-4DA3-A515-32CC7E6B4618 Q33785103-3BE7F245-2959-40C1-9EC1-2462A73D0FB2 Q33954123-613EEAD4-A1B9-4AD5-AF69-2F3B05983499 Q33955720-BB12756E-2EB9-42A4-A3C8-620E88549766 Q34306503-CF9BE78C-5D54-48BB-BD9D-854C6278EC8E Q34408794-FAFBA99A-9144-4CBD-BB59-553C8F9BD415 Q34477424-5CD6F15C-FCDA-4870-B0A9-EF14FFC61299 Q34543066-5E8C760A-BF8F-4084-8D1C-5D2B2E4F95DF Q34549227-444FE9D1-E1A6-4A8A-AF48-B63BB648A69A Q35189847-4A81B2CE-2AD2-4A4B-A738-541E571F0D35 Q35328111-48DA2595-70E7-4011-983E-ADD5AE5D6259 Q35612358-3CC8C3C8-6940-4915-92CE-FA4CB2860A09 Q35802508-AA5F7CD4-79B9-4DA7-8C56-AE6568E5D283 Q35828614-F5464AB8-5196-4B34-8C64-B814A096E19C Q36000835-8B80A58A-A0DF-4AFE-B6C9-570A8AB15816 Q36141581-2D2BDCA2-DD91-4F7F-A3CB-53F0037F1834 Q36173439-2725D24A-0A43-4BFD-982D-F7597C18CCD1 Q36269232-68C98773-EC92-41BF-8BF1-F3884E738E78 Q36486902-4CDE9D7D-6FFE-4198-A816-87F4EED19D2E Q36685395-838758EF-A799-403C-A5D5-6A9F6E0CA282 Q36806906-C782C187-FF29-43A3-A08A-CAC91D7CFB73 Q37040756-79DE8713-4163-45E7-A46B-4DDEDECF27D2 Q37053820-DE7975E8-0302-4CA5-8D83-4A346CB6A321 Q37191649-6C09BA01-2F22-4599-A3AC-C63DB0161E4D Q37193493-4D7ED491-015C-4EE8-816A-732E02768F8B

P2860

Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer

http://www.wikidata.org/entity/Q33862861

description

2013 nî lūn-bûn

@nan

2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer

@ast

Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer

@en

type

label

Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer

@ast

Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer

@en

prefLabel

Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer

@ast

Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer

@en

P1433

Q33862861-098F01BA-D741-4F85-8A3F-3F5352F0C6E0

P1476

Q33862861-640701B6-00C6-4D0D-888E-B1B3BDDD322B

P2093

Q33862861-0CDDDBD0-4342-488E-96D5-3C384D479BD7

Q33862861-23C90998-5F60-4368-BC3A-FB7B3B93319F

Q33862861-628CC939-7BAC-4CAE-B783-36272B984135

P2860

Q33862861-01E366AE-9F3E-4857-A584-837DCC4CD2AC

Q33862861-07620B8D-2E41-41CA-A5EB-E1CC8E2E4727

Q33862861-07F2C901-8852-4813-8B6A-F25D2D3320DB

Q33862861-083E7620-C90E-4173-B8AD-C2DBCB2B2B0C

Q33862861-103ABCEA-8A42-41AD-BE1A-03BD3043284A

Q33862861-16A7D069-EAE9-43D6-A914-F424460F74E3

Q33862861-17AC8AE8-63DD-44A7-927B-D13300FBB7DA

Q33862861-1D8CB3DF-8FFA-413D-AF04-1AD4D70A5B13

Q33862861-21CAF024-D1D4-4718-8E25-A4CAEEB75BF1

Q33862861-267E821E-30D5-40C8-A594-B4FF3BF5E7B3

P2888

Q33862861-4A81EEED-6F82-4F09-9F45-F99C9B98984E

P304

Q33862861-A0FA27D0-588D-4321-B393-4E29F009914E

P31

Q33862861-B3E69900-B35F-43E5-8E7A-623A9709B8FF

P356

Q33862861-1E3DA8C8-86C3-4628-B714-FB0ACE647F1E

P407

Q33862861-2EFE0F8A-5920-4B52-B26A-7E55A51FB61B

P433

Q33862861-3C9289D8-C158-4B16-A13F-775050249214

P478

Q33862861-E16D43FD-45C2-4904-9A4B-66D739018332

P577

Q33862861-1AE35FA6-8B52-4D0D-B9F3-5B07C64C9FE2

P6179

Q33862861-0866B97A-F88A-4B77-BF38-BDE4F5C2CF80

P698

Q33862861-FDF235DC-9E3C-4C2D-90D8-DF29729CF563

P921

Q33862861-0668F4AB-3D9E-4160-BE04-83CCF10FA8AE

Q33862861-F3290429-174C-41EC-A34C-116E633F4CC6

P932

Q33862861-3CDFA5B0-8DA8-40F4-82DE-4EC55B5513EA

P356

NRCLINONC.2013.208

P1433

Nature Reviews Clinical Oncology

P1476

Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer

@en

P2093

Charles G Drake

http://www.w3.org/2001/XMLSchema#string

Evan J Lipson

http://www.w3.org/2001/XMLSchema#string

Julie R Brahmer

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer immunotherapy: moving beyond current vaccines

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma

Nivolumab plus ipilimumab in advanced melanoma.

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

The blockade of immune checkpoints in cancer immunotherapy

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

P2888

nrclinonc.2013.208

P304

24-37

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRCLINONC.2013.208

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2013-11-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1043102499

http://www.w3.org/2001/XMLSchema#string

P698

24247168

http://www.w3.org/2001/XMLSchema#string

P921

P932

4086654

http://www.w3.org/2001/XMLSchema#string